Jérusalem

March of the Living launches global interfaith initiative to commemorate Kristallnacht: #LetThereBeLight

Tuesday, October 20, 2020 - 1:00pm

On November 9, 2020, March of the Living will mark Kristallnacht with a message of unity and hope, through a unique international campaign.

Key Points: 
  • On November 9, 2020, March of the Living will mark Kristallnacht with a message of unity and hope, through a unique international campaign.
  • As part of this historic virtual initiative, people from all over the world will be able to add their voice to the campaign.
  • Personal messages and prayers from the virtual campaign will be projected on the walls of the Old City of Jerusalem.
  • March of the Living is the largest annual international Holocaust education program of its kind in the world.

March of the Living launches global interfaith initiative to commemorate Kristallnacht: #LetThereBeLight

Tuesday, October 20, 2020 - 1:00pm

On November 9, 2020, March of the Living will mark Kristallnacht with a message of unity and hope, through a unique international campaign.

Key Points: 
  • On November 9, 2020, March of the Living will mark Kristallnacht with a message of unity and hope, through a unique international campaign.
  • As part of this historic virtual initiative, people from all over the world will be able to add their voice to the campaign.
  • Personal messages and prayers from the virtual campaign will be projected on the walls of the Old City of Jerusalem.
  • March of the Living is the largest annual international Holocaust education program of its kind in the world.

Friends of Zion Museum Honors Eleven World Leaders at Israel's 4th Annual Christian Media Summit

Sunday, October 18, 2020 - 6:46pm

JERUSALEM, Oct. 18, 2020 /PRNewswire/ --The Israeli government's 4th Annual Christian Media Summit was held this evening, Sunday October 18, at the Friends of Zion Heritage Center in Jerusalem.

Key Points: 
  • JERUSALEM, Oct. 18, 2020 /PRNewswire/ --The Israeli government's 4th Annual Christian Media Summit was held this evening, Sunday October 18, at the Friends of Zion Heritage Center in Jerusalem.
  • For the first time ever, the event was held virtually, with its program broadcast to millions of viewers all around the world.
  • Dr. Mike Evans, the founder of the Friends of Zion Heritage Center, had announced that during the summit the prestigious Friends of Zion Award would be presented to eleven world leaders, including two kings, one prime minister, one sultan, one crown prince, and six presidents.
  • This award has been given to world leaders who have stood by and supported the State of Israel and the Jewish people.

BrainsWay Debuts “#TheRealOCD” Campaign and Video on Obsessive-Compulsive Disorder (OCD)

Tuesday, October 13, 2020 - 2:00pm

(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced its #TheRealOCD campaign in conjunction with Obsessive-Compulsive Disorder (OCD) Awareness Week, which takes place October 11 17, 2020.

Key Points: 
  • (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced its #TheRealOCD campaign in conjunction with Obsessive-Compulsive Disorder (OCD) Awareness Week, which takes place October 11 17, 2020.
  • The campaign features an original video starring mental health influencers Kait Miller ( @kaitgmiller) and Rachel Novak ( @rachel.novak ) who discuss the common misuse of the phrase OCD in popular culture.
  • The video also features real stories of patients actually suffering from OCD, and reveals insights on the true nature of living with this traditionally difficult-to-treat disorder.
  • We hope this video facilitates increased education around what real OCD looks like, and conveys that it can be successfully treated.

Yael Eckstein named one of "The World's 50 Most Influential Jews" by The Jerusalem Post

Thursday, October 8, 2020 - 12:30pm

JERUSALEM, Oct. 8, 2020 /PRNewswire/ --In September, Yael Eckstein, the president and CEO of the International Fellowship of Christians and Jews (The Fellowship), was included on the Jerusalem Post's prestigious list of the world's 50 most influential Jews.

Key Points: 
  • JERUSALEM, Oct. 8, 2020 /PRNewswire/ --In September, Yael Eckstein, the president and CEO of the International Fellowship of Christians and Jews (The Fellowship), was included on the Jerusalem Post's prestigious list of the world's 50 most influential Jews.
  • The Fellowship also facilitates aliyah (immigration to Israel) for Jews from around the world, and assists impoverished elderly Jews and children in the former Soviet Union.
  • Before her present duties, Yael served as global executive vice president, senior vice president, and director of program development and ministry outreach.
  • Based in Jerusalem, Yael is a published writer, leading international advocate for persecuted religious minorities, and a respected social services professional.

BrainsWay’s Deep TMS Takes Center Stage at Clinical TMS Society Annual Poster Session

Tuesday, October 6, 2020 - 2:00pm

(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that 10 of the poster presentations accepted to the annual Clinical TMS Poster session highlight the benefits and potential of Deep TMS in the treatment of mental illnesses and brain disorders.

Key Points: 
  • (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that 10 of the poster presentations accepted to the annual Clinical TMS Poster session highlight the benefits and potential of Deep TMS in the treatment of mental illnesses and brain disorders.
  • The Clinical TMS Society was established in 2013 and includes Transcranial Magnetic Stimulation (TMS) providers with extensive clinical and research experience from across the United States and the world.
  • BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
  • BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Entera Bio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Thursday, September 10, 2020 - 1:30pm

BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the H.C. Wainwright Global Investment Conference onTuesday, September 15, 2020 at 3:00 p.m. EDT.

Key Points: 
  • BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will participate virtually in the H.C. Wainwright Global Investment Conference onTuesday, September 15, 2020 at 3:00 p.m. EDT.
  • To access a live webcast of the fireside chat on the Investor Relations page of Enteras website, please click here .
  • A replay of the webcast will be archived on Enteras website for approximately 45 days following the presentation.
  • Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com .

BrainsWay Announces Presentations at Upcoming Investor Conferences

Wednesday, September 2, 2020 - 12:00pm

CRESSKILL, N.J. and JERUSALEM, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference.

Key Points: 
  • CRESSKILL, N.J. and JERUSALEM, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference.
  • BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.
  • BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.
  • To learn more, please visit www.brainsway.com

BrainsWay Receives FDA Clearance for Smoking Addiction in Adults

Monday, August 24, 2020 - 12:00pm

This FDA clearance represents a significant milestone for BrainsWay and our Deep TMS platform technology, stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay.

Key Points: 
  • This FDA clearance represents a significant milestone for BrainsWay and our Deep TMS platform technology, stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay.
  • Weekly abstinence was defined as a subjects self-report (in a diary) of no smoking, confirmed by urine tests indicating abstinence from smoking.
  • The addiction to nicotine, similar to the addiction to drugs and alcohol, involves modulation of the brain reward system and causes uncontrollable desire to smoke.
  • BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results

Thursday, August 20, 2020 - 11:30am

These interim data mark the first time Entera has evaluated the BMD effect of EB613, and we are pleased with the results to date.

Key Points: 
  • These interim data mark the first time Entera has evaluated the BMD effect of EB613, and we are pleased with the results to date.
  • As a result, these interim lumbar spine BMD data are supportive of the 2.5 mg dose we recently added to the ongoing Phase 2 study.
  • Several potential candidates are currently being evaluated, and Entera expects to provide an update on target selection by the end of 2020.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.